Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Bioresources and Agriculture / 生物資源暨農學院
  3. Agricultural Chemistry / 農業化學系
  4. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach
 
  • Details

Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach

Journal
EBioMedicine
Journal Volume
36
Pages
241-251
Date Issued
2018
Author(s)
Cheng A.N.
Lo Y.-K.
Lin Y.-S.
Tang T.-K.
CHUN-HUA HSU  
Hsu J.T.-A.
Lee A.Y.-L.
DOI
10.1016/j.ebiom.2018.09.030
URI
https://scholars.lib.ntu.edu.tw/handle/123456789/446128
URL
https://www2.scopus.com/inward/record.uri?eid=2-s2.0-85054356007&doi=10.1016%2fj.ebiom.2018.09.030&partnerID=40&md5=1aee80d44010a9d0237ed92a6abb2782
Abstract
Background: Cdc7-Dbf4 is a conserved serine/threonine kinase that plays an important role in initiation of DNA replication and DNA damage tolerance in eukaryotic cells. Cdc7 has been found overexpressed in human cancer cell lines and tumor tissues, and the knockdown of Cdc7 expression causes an p53-independent apoptosis, suggesting that Cdc7 is a target for cancer therapy. Only a handful Cdc7 kinase inhibitors have been reported. All Cdc7 kinase inhibitors, including PHA-767491, were identified and characterized as ATP-competitive inhibitors. Unfortunately, these ATP-competitive Cdc7 inhibitors have no good effect on clinical trial. Methods: Here, we have developed a novel drug-screening platform to interrupt the interaction between Cdc7 and Dbf4 based on Renilla reniformis luciferase (Rluc)-linked protein-fragment complementation assay (Rluc-PCA). Using drug repositioning approach, we found several promising Cdc7 inhibitors for cancer therapy from a FDA-approved drug library. Findings: Our data showed that dequalinium chloride and clofoctol we screened inhibit S phase progression, accumulation in G2/M phase, and Cdc7 kinase activity. In addition, in vivo mice animal study suggests that dequalinium chloride has a promising anti-tumor activity in oral cancer. Interestingly, we also found that dequalinium chloride and clofoctol sensitize the effect of platinum compounds and radiation due to synergistic effect. In conclusion, we identified non-ATP-competitive Cdc7 kinase inhibitors that not only blocks DNA synthesis at the beginning but also sensitizes cancer cells to DNA damage agents. Interpretation: The inhibitors will be a promising anti-cancer agent and enhance the therapeutic effect of chemotherapy and radiation for current cancer therapy. Fund: This work was supported by grants from the Ministry of Science and Technology, Ministry of Health and Welfare, and National Health Research Institutes, Taiwan. ? 2018 The Author(s)
Subjects
Cancer therapy; Cdc7 inhibitor; Drug repositioning; Protein fragment complementation assay; Protein-protein interaction
SDGs

[SDGs]SDG3

Other Subjects
adenosine triphosphate; antineoplastic agent; Cdc7 Kinase Inhibitor; cisplatin; clofoctol; Dbf4 dependent kinase; dequalinium; Drf1 dependent kinase; olive oil; plasmid DNA; protein kinase inhibitor; unclassified drug; antineoplastic agent; CDC7 protein, human; cell cycle protein; DBF4 protein, human; protein binding; protein kinase inhibitor; protein serine threonine kinase; antineoplastic activity; Article; autoradiography; bioluminescence; cancer therapy; carcinogenesis; cell death; cell viability; cell viability assay; controlled study; cytotoxicity; DNA damage; drug repositioning; drug screening; enzyme activity; flow cytometry; fluorescence microscopy; gene; growth inhibition; high throughput screening; human; human cell; immunoblotting; immunoprecipitation; irradiation; male; mouse; nonhuman; nuclear localization signal; peptide synthesis; polymerase chain reaction; priority journal; protein interaction; protein phosphorylation; protein protein interaction; randomized controlled trial; Renilla reniformis; Rluc gene; therapy effect; tumor growth; tumor volume; Western blotting; animal; antagonists and inhibitors; chemistry; disease model; dose response; drug development; drug effect; gene expression; metabolism; molecular model; molecularly targeted therapy; procedures; protein conformation; reporter gene; structure activity relation; tumor cell line; Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Drug Repositioning; Drug Screening Assays, Antitumor; Gene Expression; Genes, Reporter; High-Throughput Screening Assays; Humans; Male; Mice; Models, Molecular; Molecular Targeted Therapy; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein-Serine-Threonine Kinases; Structure-Activity Relationship; Xenograft Model Antitumor Assays
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science